2023-04-17 09:29:36 ET
Shares of Inovio Pharmaceuticals ( NASDAQ: INO ) rose ~7% pre-market Monday after announcing that data from an early-stage trial for its Ebola booster vaccine candidate INO-4201 was presented at a medical event in Europe.
The Phase 1b study was designed to evaluate INO-4201 in healthy adult participants who previously received a single injection of Ervebo, an FDA-approved vaccine to prevent disease caused by Zaire ebolavirus.
"Preliminary data showed that INO-4201 was well tolerated and produced a strong immune response," remarked Dr. Angela Huttner, the lead investigator of the trial and the Infectious Disease Consultant at Geneva University Hospitals.
In February, Inovio ( INO ) posted initial data from the trial, noting that INO-4201 was well-tolerated and boosted antibody response in 100% (36 of 36) of those who received it.
The company said that today's presentation included new humoral and cellular response data to indicate the potential of INO-4201 in restoring antibody titers to a level that can deliver protection against the infection from Zaire ebolavirus.
Read: Seeking Alpha analyst Out of Ignorance reaffirmed Neutral rating on INO this month, noting that the biotech lacked near-term catalysts despite its compelling valuation.
For further details see:
Inovio gains on Phase 1 data for Ebola booster shot